Voyageur Pharmaceuticals Ltd.
VYYRF · OTC
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.12 | 0.23 | -0.14 |
| FCF Yield | -78,445.20% | -17.13% | -19.76% | -22.17% |
| EV / EBITDA | 82.74 | -4.77 | -5.78 | -4.23 |
| Quality | ||||
| ROIC | -0.30% | -81.95% | -116.35% | -100.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.18 | 0.71 | 0.98 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 69.50% | 50.48% | 4.06% | -380.59% |
| Safety | ||||
| Net Debt / EBITDA | 82.99 | -0.03 | 0.00 | 0.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -601.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.21 | 0.28 | 0.23 |
| Cash Conversion Cycle | 0.00 | -34,694.38 | -72,922.56 | -93,435.29 |